Moderna has touted the possibility of an accelerated approval for its Merck-partnered cancer vaccine by 2025. But according to executives, three things need to happen first.
Merck and Moderna made news in December 2022 when they unveiled Phase II data suggesting their individualized neoantigen therapy, or INT, reduced the risk of cancer recurrence or death in melanoma patients when used with Merck’s Keytruda. The data reinvigorated a field that has frustrated scientists for years. The therapy is now in two Phase III trials in adjuvant melanoma and non-small cell lung cancer.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.